The purpose and scope of this report
- This report aims to be the essential resource for potential investors in and licensors of China's innovative therapeutic candidates
- This report provides an overview of new drug research and development in China and highlights key issues and trends
- This report provides a database of new drug candidates innovated and under development in China and includes the candidate's sponsor entity, stage of development, type of therapeutic, intended indication, and in some cases patent status and additional information
- Included in the pipeline: Novel therapeutics (not marketed anywhere in the world)
• Chemical entities
• NCE
• Single compound derived from TCM
• Biological products
• Gene therapies
• Vaccines
• Antibody therapeutics
• Recombinant proteins
Who would benefit from this report?
- Pharmaceutical and biotechnology company
• Executives
• Licensing professionals
• Business/Strategy development professionals
• Research and development directors and managers
- Investors
- Regulators
- Others who require information concerning new drug development in China
Why is this report unique?
No other comprehensive attempt to document new drug candidates in China currently exists
Methodology
Collecting information in China is a labor-intensive and difficult task. To gather the data contained in this report, GB analysts rely heavily on primary sources. For each candidate, GB talks directly with the researchers on a repeated basis to keep information correct and up to date. Sources and methods include:
- China's funding documentation
- Interviews
• Technology transfer offices of institutes and universities
• Biotechnology and pharmaceutical companies
• Consulting and information companies
• Leaders, managers, scientists within the drug R&D industry
• Associations and government offices
- Patent office searches
- Internet
|